Corrigendum to 'Inhibition of HDACs-EphA2 signaling axis with WW437 demonstrates promising preclinical antitumor activity in breast cancer' [EBioMedicine 31 (2018) 276-286].

Zhang T, Li J, Ma X, Yang Y, Sun W, Jin W, Wang L, He Y, Yang F, Yi Z, et al. Corrigendum to 'Inhibition of HDACs-EphA2 signaling axis with WW437 demonstrates promising preclinical antitumor activity in breast cancer' [EBioMedicine 31 (2018) 276-286]. EBioMedicine. 2020;52:102629.